Safe Harbor Locus Transgene Integration for Malignancy Risk Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in achieving safe, durable, and high-level expression of transgenes, particularly in mitotically active tissues, due to issues like random integration leading to malignancy risks and gene silencing, and limited duration of expression.
Innovation Solution
The development of zinc-finger proteins (ZFPs) and Transcription Activator-Like Effector (TALE) nucleases that specifically bind to target sites in the genome, such as the albumin gene, to enable precise insertion and expression of transgenes, using engineered zinc-finger binding domains and nuclease cleavage domains for targeted integration and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If random integration of transgene is used, then durable expression is achieved, but risk of malignancy increases due to untargeted insertion
Solution Approach 1:
The patent applies local quality by creating a specific safe harbor locus (ROSa26) with unique properties that allow transgene integration without the harmful effects of random integration. This locus is specifically engineered to provide controlled expression and avoid oncogene activation, making the integration site locally optimized for safety and durability.
Solution Approach 2:
The patent uses an intermediary approach by introducing a defined safe harbor locus that mediates between the need for durable expression and the risk of malignancy. This intermediary site acts as a controlled interface for transgene integration, providing the benefits of integration-based durability while eliminating the safety risks through its specifically designed regulatory elements and genomic context.
2Reliability
If transgene integration into safe harbor locus is used, then safety is improved, but expression level may be insufficient for therapeutic effect
Solution Approach 1:
The patent applies parameter changes by modifying the safe harbor locus to include enhanced regulatory elements such as strong promoters and enhancers that increase transgene expression levels. The ROSa26 locus is engineered with specific chromatin features and transcriptional control elements that optimize expression magnitude while maintaining the safety advantages of targeted integration.
3Ease of operation
If exogenous promoter is fused to transgene, then expression control is achieved, but promoter silencing occurs over time
Solution Approach 1:
The patent applies the taking out principle by removing the problematic exogenous promoter from the transgene construct and instead utilizing the endogenous promoter and regulatory elements of the safe harbor locus (ROSa26) to drive transgene expression. This extraction of the exogenous promoter eliminates the silencing issue while the locus-specific regulatory elements provide sustained expression control.
Solution Approach 2:
The patent implements self-service by enabling the safe harbor locus itself to provide the necessary expression control through its endogenous regulatory elements. The ROSa26 locus is designed with intrinsic promoter and enhancer sequences that autonomously regulate transgene expression without requiring external promoter sequences, thereby avoiding promoter silencing while maintaining long-term expression.
4Quantity of substance
If episomal delivery method is used, then high initial expression is achieved, but expression duration is limited due to lack of robust replication
Solution Approach 1:
The patent applies merging by combining the advantages of episomal delivery (high initial expression) with the advantages of integrated delivery (durability). The transgene is designed with strong expression elements for immediate high expression, while simultaneously being integrated into the safe harbor locus for stable maintenance and long-term expression in mitotically active tissues.
Data Source
AI summary
Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.